Discussion  by unknown
Previous generations of cardiologists have advocated
medical management of severe AS until symptoms are well
established. It was stated in a recent editorial, ‘‘We, like
most cardiologists, no longer believe that surgery is the
most common cause of sudden death in asymptomatic pa-
tients with aortic stenosis.’’16 Results of the present study
support the idea of early intervention in patients with a diag-
nosis of severe asymptomatic AS when there is a low institu-
tional perioperative mortality. It is possible that future studies
that include risk stratification will improve patient selection
for AVR.
Conclusions
At 3 years, 52% of asymptomatic patients with severe AS had
symptoms develop, had AVR, or had died. Patients with
severe AS who present without symptoms do not have
greater operative and long-term mortalities if they undergo
elective AVR after the development of symptoms. Impor-
tantly, however, patients who had symptoms and patients
who remained asymptomatic and had AVR had a survival
advantage when compared with asymptomatic patients who
had medical management alone.
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Discussion
DrMichael A. Acker (Philadelphia, Pa). This paper is very impor-
tant. I believe its import lies not in the extraordinary low mortality,
for which the Mayo cardiac surgeons are to be congratulated, but
rather in this very careful observation of the natural history of
asymptomatic AS and also the similarities in the operative mortality
between the asymptomatic and symptomatic patients undergoing
AVR. I have three questions, which I will ask one at a time to
give you a chance to answer.
Although you showed overall survival and benefit for just getting
the valve replaced, 50% of your patients remained asymptomatic
without AVR and without death at 3 years. Did you look at this
group to determine preoperative characteristics such as the presence
of left ventricular hypertrophy, for instance, that would be predictive
of a benign course so that we do not have to operate on everyone
who has severe AS?
Dr Brown.We did not specifically look at that group of patients.
However, in a previous study, both a smaller aortic valve area and
left ventricular hypertrophy predicted symptom development in pa-
tients with asymptomatic AS.
Dr Acker. Second question: As you know, the operative mortal-
ity across the country for AVR and aortic valve and coronary bypass
surgery, according to The Society of Thoracic Surgeons database, is
not 1% and 2% but rather 3.5% for AVR alone and nearly 6% for an
AVR/coronary bypass. It is thus imperative, if one is considering
operating on the asymptomatic patient, to know the true operative
result. On the other hand, to complete that risk/benefit analysis,
one would have to know the rate of sudden death if we are going
to wait in the asymptomatic group and the factors that would predict
sudden death. Do you have some information on that?
Dr Brown. I cannot help you with the factors that will predict
sudden death; however, I can tell you that the rate of sudden death
in this cohort was approximately 1% per year. As you can see,
with an operative mortality of 1%, it is a reasonable decision to
operate in these patients.
Dr Acker. Finally, did you look at the need for coronary bypass
surgery or the ischemic burden as an independent risk factor for the
development of symptoms or long-term survival?
Dr Brown. Again, we did not specifically look at patients who
did or did not have coronary artery bypass grafting except for in
our multivariate model.
Dr Paul Kurlansky (Miami, Fla). You demonstrated very
nicely that AVR was an independent risk factor for lower mortality,
but obviously both in the symptomatic and the asymptomatic pa-
tients, the decision not to operate was based on many factors. Did
you use propensity analysis or any other method to try to match pa-
tients who did not have surgery with patients who did have surgery
to see whether you could discern other independent factors that
would have led to the decision not to operate?
In other words, it would seem as though merely waiting and
watching is not necessarily a wise decision, but that is not necessar-
ily the decision that was made. The decision not to operate may have
been a conscious one based on other risk factors that may
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themselves have been predisposed to mortality. Therefore, the deci-
sion not to operate is really a surrogate for other factors. I was won-
dering whether you used any statistical method to try to explore this.
Dr Brown. No, we did not use any type of statistical methods
such as propensity matching. The problem is that trying to identify
retrospectively why patients did not have surgery is always difficult,
and as mentioned, our beliefs are that there are several reasons.
Some patients are not referred, some patients are elderly and frail
and do not wish to have surgery, and some patients, of course,
have cancer or dementia, which may preclude an invasive proce-
dure.
DrWade L. Knight (Temple, Tex). I noticed from the summary
in the book that you did not include anyone in your group with an
ejection fraction less than 40%. Admittedly, that makes your statis-
tics look better in your outcomes, but I think what those of us in the
audience need to know is what do the real life group of patients look
like? Many of the people that might have been turned down for sur-
gery may have been turned down because of low ejection fractions
or high creatinine values. You are probably familiar with the article
in the December 2006 issue of The Annals of Thoracic Surgery, I
think out of Loma Linda, addressing the large percentage of patients
with AS turned down or never referred for aortic valve surgery. At
your institution, did you refuse AVR for patients with ejection frac-
tions less than 40%, or did you just not include them in this report?
Dr Brown. Just to make it clear, of the original cohort of patients
who were identified with asymptomatic AS, only 3% had an ejection
fraction of less than 50%. We did not specifically exclude any pa-
tient simply for having a low ejection fraction in our surgical series.
Dr Ahmed El Gamel (London, United Kingdom). The question
of mortality from your paper is quite clear: you have a low operative
mortality. However, one question that bothers me is the morbidity of
replacing a valve in a patient who is asymptomatic. Complications
like stroke, even if it is a minor one, will make the patient stay in
the hospital for a period of time. Have you any feeling of how
much morbidity the asymptomatic patients have experienced and
how long the hospital stay was for patients who needed readmission
for any complications after surgery?
Dr Brown.We do not look at specific data on the length of stay
after surgery. As was shown, the mortality after surgery is similar to
that of an age- and gender-matched population. However, you are
correct; we did not specifically look at the burden of morbidity in
a patient who receives an AVR.
DrChristopherM. Feindel (Toronto, Ontario, Canada).When
determining whether patients have symptoms or not, was there con-
sistency in obtaining a good history? I know that sounds pretty ba-
sic, but I think if you question patients you will often pick out
symptoms that, believe it or not, even the cardiologist might not
pick up.
Dr Brown. This study stretched over a long period of time, be-
ginning in 1984, and there was no systematic objective assessment
such as an exercise stress test. However, a cardiologist did review all
these patient charts to determine that this was an actual asymptom-
atic patient.
Dr A. W. Atkinson (Raleigh, NC). I think it is an interesting
study and it is sort of a negative study. It shows that symptoms do
not really predict the outcome of surgery. You would think other-
wise, that the more symptomatic patients are going to have a little
tougher time or a higher mortality, but that is not true. It seems
that it is very subjective, and I think we need to be much more de-
finitive. We have seen this with mitral valve disease; lots of asymp-
tomatic people’s ventricles are deteriorating. It has been my
impression that people are fairly asymptomatic, but a lot of these
people are not very active. They do not do a whole lot and the big-
gest thing in their life is to get surgery. We really need more objec-
tive criteria than just how the patient feels according to a telephone
call or when they visit the doctor. When they are afraid of surgery,
they are not going to have many symptoms. I think we need numbers
like Bonow’s mitral valve data, as someone mentioned, left ventric-
ular hypertrophy, pulmonary artery pressures, left atrial size, pres-
ence or absence of atrial fibrillation. There are a whole lot of
criteria that we need to put on these patients and see what they
have, when they have it, do they have it, and then I think we will
have a lot more sorting out as to when we need to operate on these
patients.
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